Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease

References

• CazzolaMDi MarcoFSantusPThe pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPDPulm Pharmacol Ther200417353914643169
   PubMed Web of Science ®Google Scholar
• CazzolaMCentanniSSantusPThe functional impact of adding salmeterol and tiotropium in patients with stable COPDRespir Med2004981214122115588043
   PubMed Web of Science ®Google Scholar
• CazzolaMNoschesePSalzilloADe GiglioCD’AmatoGMateraMGBronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patientsRespir Med20059952452815823447
   PubMed Web of Science ®Google Scholar
• CazzolaMTashkinDPCombination of formoterol and tiotropium in the treatment of COPD: effects on lung functionCOPD2009640441519863370
   PubMedGoogle Scholar
• BeierJvan NoordJDeansASafety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patientsInt J Chron Obstruct Pulmon Dis2012715316422419863
   PubMed Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodi-lation compared with tiotropium alone: a randomised, double-blind comparisonThorax20126778178822544891
   PubMed Web of Science ®Google Scholar
• MatsushimaSInuiNYasuiHIndacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary diseasePulm Pharmacol Ther201530111525445929
   PubMed Web of Science ®Google Scholar
• van der MolenTCazzolaMBeyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomesPrim Care Respir J20122110110822222945
   PubMedGoogle Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev20126445050422611179
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther20102325726720381630
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGCazzolaMPharmacological interaction between LABAs and LAMAs in the airways: optimizing synergyEur J Pharmacol201576116817325981302
   PubMed Web of Science ®Google Scholar
• CazzolaMRoglianiPSegretiAMateraMGAn update on broncho-dilators in Phase I and II clinical trialsExpert Opin Investig Drugs20122114891501
   PubMed Web of Science ®Google Scholar
• TashkinDPFuture of fixed-dose longacting β2-agonist and antimusca-rinic combination therapy in COPDLancet Respir Med201316724321790
   PubMed Web of Science ®Google Scholar
• SinghDNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesBr J Clin Pharmacol20157969570825377687
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPMateraMGAclidinium bromide for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother2013141205121423566013
   PubMed Web of Science ®Google Scholar
• RoglianiPCalzettaLOraJPharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchiEur J Pharmacol201576138339025952728
   PubMed Web of Science ®Google Scholar
• NiHSoeZMoeSAclidinium bromide for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20149CD01050925234126
   PubMed Web of Science ®Google Scholar
• CazzolaMCentanniSRegordaCOnset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPDPulm Pharmacol Ther200114414511162418
   PubMed Web of Science ®Google Scholar
• CazzolaMD’AmatoMCalifanoCFormoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary diseaseClin Ther20022459560412017404
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGSantangeloGVinciguerraARossiFD’AmatoGSalmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response studyRespir Med1995893573627638371
   PubMed Web of Science ®Google Scholar
• SteiropoulosPTzouvelekisABourosDFormoterol in the management of chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2008320521518686730
   PubMedGoogle Scholar
• CazzolaMCalzettaLPageCPPharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchiEur J Pharmacol201474513514325446566
   PubMed Web of Science ®Google Scholar
• CazzolaMRoglianiPMateraMGAclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother20131477578123472632
   PubMed Web of Science ®Google Scholar
• LalCStrangeCAclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother20151642743425597386
   PubMed Web of Science ®Google Scholar
• BabuKSMorjariaJBClinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary diseaseTher Adv Respir Dis20159566825754881
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLMateraMGAclidinium/formoterol fixed-dose combination for the treatment of chronic obstructive pulmonary diseaseDrugs Today (Barc)2015519710525756065
   PubMed Web of Science ®Google Scholar
• MoitraSBhomeABBrashierBBAclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to dateDrug Des Devel Ther2015919891999
   PubMed Web of Science ®Google Scholar
• AstraZeneca GlobalDuaklir® Genuair® Approved in the European Union for Chronic Obstructive Pulmonary Disease Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20141124--duaklir-genuair-approved-in-the-european-unionAccessed July 10, 2015
   Google Scholar
• European Medicines AgencyDuaklir Genuair Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003745/human_med_001811.jsp&mid=WC0b01ac058001d124Accessed July 10, 2015
   Google Scholar
• PriceDRobertsonABullenKImproved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label studyBMC Pulm Med201010120051135
   PubMed Web of Science ®Google Scholar
• GordonJGlaxoSmithKline – Upgrading to Neutral, Upside from Upcoming Catalysts Balances Out Earnings Risk Available from: https://markets.jpmorgan.com/research/email/eevpt8pp/GPS-1190044-0.pdfAccessed July 9, 2015
   Google Scholar
• BeehKMBeierJThe short, the long and the “ultralong”: why duration of bronchodilator action matters in chronic obstructive pulmonary diseaseAdv Ther20102715015920411368
   PubMed Web of Science ®Google Scholar
• CazzolaMBeehKMPriceDRocheNAssessing the clinical value of fast onset and sustained duration of action of long-acting broncho-dilators for COPDPulm Pharmacol Ther201531687825727846
   PubMed Web of Science ®Google Scholar
• WuKLoobyMPillaiGPopulation pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patientsJ Pharmacokinet Pharmacodyn20113810510921104005
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of acli-dinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J2013421484149423722616
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umecli-dinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med2014247248624835833
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J20154596997925573406
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLOraJPuxedduERoglianiPMateraMGSearching for the synergistic effect between aclidinium and formoterol: from bench to bedsideRespir Med20151091305131126303336
   PubMed Web of Science ®Google Scholar
• Di MarcoFMilic-EmiliJBoveriBEffect of inhaled bronchodila-tors on inspiratory capacity and dyspnoea at rest in COPDEur Respir J200321869412570114
   PubMed Web of Science ®Google Scholar
• KesslerRPartridgeMRMiravitllesMSymptom variability in patients with severe COPD: a pan-European cross-sectional studyEur Respir J20113726427221115606
   PubMed Web of Science ®Google Scholar
• MocarskiMCaractaCTourkodimitrisSNighttime symptoms of COPD in a clinical trial population: prevalence and impact [abstract]Am J Respir Crit Care Med2011183A1495
   Web of Science ®Google Scholar
• PriceDSmallMMilliganGImpact of night-time symptoms in COPD: a real-world study in five European countriesInt J Chron Obstruct Pulmon Dis2013859560324348032
   PubMed Web of Science ®Google Scholar
• PartridgeMRKarlssonNSmallIRPatient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet surveyCurr Med Res Opin2009252043204819569976
   PubMed Web of Science ®Google Scholar
• RocheNSmallMBroomfieldSReal world COPD: association of morning symptoms with clinical and patient reported outcomesCOPD20131067968624127914
   PubMedGoogle Scholar
• StephensonJJCaiQMocarskiMTanHDoshiJASullivanSDImpact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20151057758625844033
   PubMed Web of Science ®Google Scholar
• KuyucuTGüçlüSZSaylanBA cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE studyTuberk Toraks20115932833922233302
   PubMedGoogle Scholar
• Lopez-CamposJLCaleroCQuintana-GallegoESymptom variability in COPD: a narrative reviewInt J Chron Obstruct Pulmon Dis2013823123823687444
   PubMed Web of Science ®Google Scholar
• LeidyNKMurrayLTMonzBUMeasuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trialsRespir Res20141512425287629
   PubMed Web of Science ®Google Scholar
• MocarskiMZaiserETrundellDMakeBJHareendranAEvaluation of the psychometric properties of the Nighttime Symptoms of COPD InstrumentInt J Chron Obstruct Pulmon Dis20151047548725834415
   PubMed Web of Science ®Google Scholar
• MocarskiMHareendranAJenMHZaiserEMakeBEvaluation of the psychometric properties of the early morning symptoms of COPD instrument (EMSCI) [abstract]Value Health201417A179
   Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMHeTLeselbaumACaractaCEfficacy of fixed-dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD [abstract]Am J Respir Crit Care Med2014189A6006
   Web of Science ®Google Scholar
• MakeBDonohueJSoongWZhongXLeselbaumACaractaCEfficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: a 1-year study [abstract]Eur Respir J201444Suppl 58P2413
   Google Scholar